LLY

1,045.2

+0.07%↑

JNJ

246.17

+0.3%↑

ABBV

228.99

+0.04%↑

NVS

167.04

+1.08%↑

MRK

123.55

+1.05%↑

LLY

1,045.2

+0.07%↑

JNJ

246.17

+0.3%↑

ABBV

228.99

+0.04%↑

NVS

167.04

+1.08%↑

MRK

123.55

+1.05%↑

LLY

1,045.2

+0.07%↑

JNJ

246.17

+0.3%↑

ABBV

228.99

+0.04%↑

NVS

167.04

+1.08%↑

MRK

123.55

+1.05%↑

LLY

1,045.2

+0.07%↑

JNJ

246.17

+0.3%↑

ABBV

228.99

+0.04%↑

NVS

167.04

+1.08%↑

MRK

123.55

+1.05%↑

LLY

1,045.2

+0.07%↑

JNJ

246.17

+0.3%↑

ABBV

228.99

+0.04%↑

NVS

167.04

+1.08%↑

MRK

123.55

+1.05%↑

Search

AngioDynamics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

11.49 3.23

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.96

Max

11.46

Pagrindiniai rodikliai

By Trading Economics

Pajamos

4.6M

-6.4M

Pardavimai

3.7M

79M

Pelno marža

-7.994

Darbuotojai

675

EBITDA

4.4M

-436K

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+72.28% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-01

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-93M

452M

Ankstesnė atidarymo kaina

8.26

Ankstesnė uždarymo kaina

11.49

Naujienos nuotaikos

By Acuity

50%

50%

149 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

AngioDynamics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-23 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

2026-02-23 22:36; UTC

Uždarbis

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

2026-02-23 22:32; UTC

Uždarbis

Woodside Energy Fiscal Year Net Profit Falls 24%

2026-02-23 23:58; UTC

Rinkos pokalbiai
Uždarbis

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

2026-02-23 23:58; UTC

Rinkos pokalbiai
Uždarbis

Global Energy Roundup: Market Talk

2026-02-23 23:47; UTC

Rinkos pokalbiai

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

2026-02-23 23:43; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

2026-02-23 23:41; UTC

Įsigijimai, susijungimai, perėmimai

Crescent Capital Partners Owns 53% of ClearView Wealth

2026-02-23 23:40; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

2026-02-23 23:40; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

2026-02-23 23:40; UTC

Rinkos pokalbiai

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

2026-02-23 23:40; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

2026-02-23 23:39; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

2026-02-23 23:31; UTC

Uždarbis

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

2026-02-23 23:31; UTC

Uždarbis

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

2026-02-23 23:28; UTC

Uždarbis

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

2026-02-23 23:28; UTC

Uždarbis

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

2026-02-23 23:28; UTC

Uždarbis

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

2026-02-23 23:27; UTC

Uždarbis

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

2026-02-23 23:24; UTC

Rinkos pokalbiai

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

2026-02-23 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

2026-02-23 22:31; UTC

Uždarbis

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

2026-02-23 22:24; UTC

Uždarbis

Viva Energy Energy & Infrastructure Ebitda A$93 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy FY Underlying Ebitda A$700.9 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy Final Dividend 3.94 Australian Cents/Security

2026-02-23 22:21; UTC

Uždarbis

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

2026-02-23 22:21; UTC

Uždarbis

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

2026-02-23 22:20; UTC

Uždarbis

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Akcijų palyginimas

Kainos pokytis

AngioDynamics Inc Prognozė

Kainos tikslas

By TipRanks

72.28% į viršų

12 mėnesių prognozė

Vidutinis 19.33 USD  72.28%

Aukščiausias 24 USD

Žemiausias 16 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines AngioDynamics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

3

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

9 / 9.3Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

149 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę AngioDynamics Inc

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
help-icon Live chat